Edition:
United Kingdom

People: Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

3.64USD
17 Jul 2019
Change (% chg)

$-0.04 (-1.09%)
Prev Close
$3.68
Open
$3.68
Day's High
$3.68
Day's Low
$3.50
Volume
14,766
Avg. Vol
121,514
52-wk High
$4.79
52-wk Low
$1.75

Middleton, Fred 

Mr. Fred A. Middleton is Director of the Company. Mr. Middleton currently serves as a Managing Director of Sanderling Ventures, where he has worked for 30 years as an investor, management team member and director in over 20 new biomedical ventures built in Sanderling's venture investment portfolios since 1988. During his time at Sanderling, Mr. Middleton served as Vice Chairman and Chief Business Officer of Altor Biosciences, where he helped raise over $100M for clinical trials development and its subsequent acquisition by NantCell, Inc. Mr. Middleton was a first round investor in Regeneron Pharmaceuticals and served as a board member and as the company's CFO during its initial public offering in 1990. Earlier in his career, Mr. Middleton served as the third original member of the Genentech management team as its Chief Financial Officer. Mr. Middleton currently serves on the Board of Directors of Endocyte (ECYT), Stereotaxis (STXS), Viacyte, Inc., Lineagen, Inc. and TheraVida, Inc.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --